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Chronic and moderate consumption 
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benefits in a rat model of pulmonary arterial 
hypertension
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Dee Blackhurst1 
 Abstract 
Objectives: In pulmonary arterial hypertension (PAH), right ventricular (RV) dysfunction develops via mechanisms 
involving oxidative stress. Moderate and chronic red wine (RW) consumption reduces oxidative stress and confers 
cardioprotection but its effect on PAH is unknown. We evaluated whether moderate and chronic consumption of 
reduced‑alcohol RW (RARW) confers cardioprotection in a monocrotaline (MCT)‑induced PAH rat model.
Results: Rats were randomly grouped: control; MCT; RARW; MCT + RARW. Wine was diluted to mimic moderate 
intake for humans, and consumed from 7 days before, until 28 days after MCT‑injection. Echocardiography measured 
pulmonary artery acceleration time (PAAT) and RV thickness. Conjugated dienes (CD), and thiobarbituric acid reac‑
tive substances (TBARS) concentrations were assessed. MCT induced RV thickness and decreased PAAT compared to 
controls [1.22 ± 0.09 mm vs 0.46 ± 0.02 mm and 14 ± 1 vs 23 ± 2 m/s, respectively (p < 0.001)]. Chronic RARW con‑
sumption limited MCT‑induced RV hypertrophy and increased PAAT. CD and TBARS increased in MCT‑treated animals 
compared to controls (672 ± 43 nmol/L vs 453 ± 35 nmol/L; p < 0.01 and 13 ± 2 µmol/L vs 4 ± 0.3 µmol/L; p < 0.01). 
RARW reduced MCT‑induced CD (472 ± 27 nmol/L vs 672 ± 43 nmol/L; p < 0.01).
Conclusion: Chronic and moderate intake of RARW ameliorates MCT‑induced PAH in rats, which may be partly 
attributable to reduction of lipid peroxidation.
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Introduction
Pulmonary arterial hypertension (PAH) is a disease with 
high morbidity and mortality [1]. All PAH-related dis-
eases share common pathological features characterised 
by inflammation, pulmonary vascular remodelling, vaso-
constriction, thrombosis in  situ and right ventricular 
(RV) hypertrophy [2]. There is no cure for PAH, and cur-
rent medical treatments are limited due, at least in part, 
to the lack of knowledge of the pathophysiology of the 
disease. Recent data suggest that oxidative stress may 
contribute to pulmonary vascular dysfunction, therefore 
supporting the hypothesis that the use of antioxidants 
may be beneficial as a therapeutic approach for the dis-
ease [2, 3].
Multiple epidemiological and experimental studies sug-
gest that moderate and chronic consumption of red wine 
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both alcohol and other compounds in wine [4, 5]. Indeed, 
lowering the alcohol levels in wine does not seem to 
affect the cardioprotective effect of regular and moder-
ate consumption of wine against ischemia–reperfusion 
injury but it presents the beneficial effect of potentially 
limiting the adverse effects of alcohol [4]. In humans, 
moderate consumption of wine may decrease the risk 
of chronic obstructive pulmonary disease [6]. Although 
several components found in wine such as melatonin, 
resveratrol and quercetin present health benefits against 
PAH in animal studies, it is not known whether moderate 
and chronic consumption of wine protects against PAH 
[7–9]. Therefore, in the present study, we aimed to test 
whether chronic and moderate consumption of reduced-
alcohol RW (RARW) could limit monocrotaline (MCT)-




The study was approved by the Faculty of Health Sciences 
Animal Ethics Committee, University of Cape Town 
(under the reference number 016/001) and conducted 
at the Hatter Institute. All protocols were carried out in 
compliance with the Care and Use of Laboratory Animals 
Guide published by the United States National Institutes 
of Health in 2011. Male Long Evans rats obtained from 
the Research Animal Facility, University of Cape Town 
(RAF-UCT) weighing 150–175  g were housed in the 
Faculty of Health Sciences Animal Unit at the Univer-
sity of Cape Town, in a 12-h dark/light cycle with room 
temperatures between 20 and 23 °C and humidity main-
tained at 40%. A maximum of 4 rats were housed per 
cage. The drinking water of the rats was supplemented 
with one part of 5.5% reduced-alcohol red wine diluted to 
seven parts of water, mimicking an amount equivalent to 
approximately 1–2 glasses of wine per day in humans, as 
previously described [4, 10]. The groups were pre-treated 
with wine or water for 7  days before receiving a single 
injection of physiological saline (0.9%, 0.1  mL) or MCT 
(80  mg/kg subcutaneous, 0.1  mL), see Additional file  1: 
Figure S1.
The following randomised groups of rats were used: 
control rats (C) (n = 5) received only water; MCT 
rats (n = 7) received water and an injection of MCT; 
RARW rats (n = 5) received reduced-alcohol wine; 
MCT + RARW rats (n = 7) received RARW and an injec-
tion of MCT. The total duration of the study was 35 days, 
which included the 7 days of pre-treatment with RARW 
or water, and 28 days following the MCT injection. Echo-
cardiography was performed on all the rats on day -7 and 
again on day 28, see Additional file 1: Figure S1.
Blood sample collection and euthanasia
At 28  days, deep unconsciousness was induced using 
40  mg/kg of Sodium Pentobarbital (intraperitoneally) 
mixed with phosphate buffered saline (PBS) after anes-
thetising with isoflurane. Blood samples of approximately 
6  mL each were drawn by cardiac puncture, after thor-
acotomy using a 25G needle into a serum gel separa-
tor tube and an EDTA anticoagulant tube as previously 
described [8]. Sample tubes were gently mixed and cen-
trifuged for 15  min at 2500×g. Serum and plasma were 
stored in aliquots at − 80  °C until analysed. Once the 
blood was collected, the heart was excised from the chest 
cavity for the biometric measurements.
Biometric measurements
Hearts and livers were removed, rinsed with PBS, lightly 
dried with a paper tissue and weighed. The RV was sep-
arated from the LV plus septum, and their masses were 
recorded. The length of the right tibia of every rat was 
also recorded. The ratios of the mass of the RV to the LV 
plus septum, to tibia length and to the whole heart were 
calculated and used for different indices of RV hypertro-
phy [8]. Relative changes of liver mass were determined 
by dividing the mass of the liver by the body mass [11].
Echocardiography
At day-7 and at the end of the study (total of 35  days), 
the rats were slightly anesthetised with 1.5–2% isoflurane 
and positioned in the supine position on a warming pad. 
Closed chest high-resolution echocardiography was per-
formed with a VEVO 2100 ultrasound system (Fujifilm, 
Visualsonics, Ontario, Canada) and a 13–25 MHz linear 
array transducer. LV chamber size and ejection fraction 
were obtained from 2 dimensional and M-mode meas-
urements at the mid-papillary level. To assess LV dias-
tolic function, both mitral E and A wave peak velocities 
were obtained from pulse-wave Doppler in the apical 
4-chamber view; the E/A ratio was then calculated. From 
pulse-wave Doppler tracing of pulmonary outflow in the 
parasternal view at the level of the aortic valve, pulmo-
nary artery acceleration time (PAAT) was measured as 
the flow time from start to peak velocity and normalised 
to total RV ejection time; velocity–time integration (VTI) 
was also calculated. PAAT/ ejection time ratio was used 
as a surrogate marker of PAH [12]. Tricuspid annular 
plane systolic excursion (TAPSE), a marker of systolic RV 
function, was obtained from the apical 4-chamber view. 
Finally, to assess RV hypertrophy, diastolic thickness of 
the RV free wall was measured. All measurements were 
made off-line on the mean of at least three consecutive 
cardiac cycles with the software resident on the ultra-
sound system.
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Histology of hearts
The RV as well as the LV plus septum were fixed in buff-
ered 4% formalin, embedded in paraffin and sectioned 
longitudinally at a thickness of 5  µm for histological 
staining and analysis. Sections were examined micro-
scopically with a Nikon Eclipse 90i microscope using a 
20X objective. Images were captured and analysed using 
ImageJ software (https:// imagej. nih. gov/ ij/ index. html) 
and data expressed as percentages of collagen deposition 
per total area sectioned [13].
Antioxidant and oxidant analyses
Blood plasma superoxide dismutase (SOD) and catalase 
activity determination The SOD activity assay was meas-
ured as preciously described by McCord and Fridovich 
[14]. The rate of reduction was measured spectrophoto-
metrically at 550 nm over 5 min intervals from time zero 
with a microplate data acquisition program (SoftMax® Pro 
4.8). The final reaction slope was determined from the use 
of a SOD standard curve and the SOD activity expressed 
as international units per milligram protein (IU/mg pro-
tein). Catalase activity was evaluated by the reduction of 
 H2O2 using the method of Aebi [15]. Plasma samples were 
diluted 1:10 in 50 mmol/L phosphate buffer, pH 7.0. The 
diluted samples (10μL) were added to a Costar® (Corn-
ing) 96-well, UV-transparent plate (Sigma-Aldrich, SA), 
with 10 μL of 50 mM phosphate buffer, pH 7.0 and 220μL 
of a freshly prepared solution of 40 mmol/L (from 30%) 
 H2O2. The rate of decomposition of  H2O2 was meas-
ured spectrophotometrically (SPECTRAmaxPLUS-384) 
from changes in absorbance at 240 nm over 5 min, rela-
tive to a blank (20 μL phosphate buffer plus 220 μL of the 
40 mmol/L  H2O2). The activity of catalase was expressed 
as international units/mg protein using a molar extinction 
coefficient of  H2O2 at 240 nm = 43.6  M−1  cm−1.
Plasma concentration of  lipid peroxidation products 
(TBARS and  CD) Lipid peroxidation was determined 
by measuring malondialdehyde (MDA), a lipid peroxida-
tion product which is measured by the thiobarbituric acid 
reactive substances (TBARS) assay method of Asakawa 
and Matsushita [16]. Conjugated dienes (CD), as initial 
markers of lipid peroxidation, were measured in cyclohex-
ane at a wavelength of 234 nm after an initial Folch extrac-
tion of the plasma [17].
Statistical analysis
The data obtained were analysed using GraphPad Prism 
version 6.00 for windows, GraphPad software (La Jolla, 
CA USA). ANOVA was used for comparing several 
groups. Where significant differences were observed 
using the two-way ANOVA, post-hoc Bonferroni’s test 
was used to evaluate differences within groups. The data 
were reported as mean ± standard error of the mean 
(SEM). Statistical significance was set at p < 0.05.
Results
Biometric measurements
At the end of the experiments, all groups had similar body 
mass, heart mass and liver mass as shown in Table 1. A 
single subcutaneous injection of MCT increased the RV 
mass, RV mass/tibia length, the RV/(LV + septal mass) 
and decreased (LV + septal mass)/heart mass compared 
Table 1 The effect of RARW consumption on biometric measurements in rats
Rats consumed wine for 7 days before and 28 days after being injected with PAH‑inducing MCT
Values are means ± S.E.M
C Control, MCT monocrotaline, RARW reduced‑alcohol red wine, RV right ventricular, LV left ventricular
*p < 0.05 (vs C); †p < 0.05 (vs MCT); n ≥ 5 per group
C MCT RARW MCT + RARW 
Body mass (g) 311.9 ± 21.6 292.6 ± 4.2 291.0 ± 16.3 283.9 ± 12.6
Whole heart mass (g) 1.59 ± 0.11 1.65 ± 0.08 1.44 ± 0.07 1.47 ± 0.10
RV mass (g) 0.23 ± 0.03 0.39 ± 0.03* 0.23 ± 0.04† 0.29 ± 0.04
Liver mass (g) 18.18 ± 1.30 17.29 ± 0.51 17.49 ± 0.62 17.13 ± 0.89
Tibia length (cm) 4.80 ± 0.20 4.81 ± 0.07 5.02 ± 0.02 4.64 ± 0.12
LV + septal mass (g) 0.93 ± 0.04 0.86 ± 0.03 0.91 ± 0.03 0.89 ± 0.06
(LV + septal mass)/heart mass (g/g) 0.59 ± 0.02 0.52 ± 0.01* 0.64 ± 0.02 0.61 ± 0.02†
Heart mass/tibia length (g/cm) 0.33 ± 0.03 0.34 ± 0.02 0.29 ± 0.01 0.32 ± 0.02
RV/(LV + septal mass) (g/g) 0.24 ± 0.03 0.45 ± 0.02* 0.25 ± 0.03 0.32 ± 0.03†
RV/tibia length (g/cm) 0.047 ± 0.007 0.081 ± 0.006* 0.045 ± 0.007† 0.063 ± 0.008
Heart mass/body mass (g/g) 0.0052 ± 0.0008 0.0057 ± 0.0003 0.0050 ± 0.0002 0.0052 ± 0.0004
Liver mass/body mass (g/g) 0.061 ± 0.009 0.059 ± 0.002 0.060 ± 0.002 0.060 ± 0.001
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to the control group, (p < 0.05). Chronic and moderate 
consumption of RARW given in rats receiving MCT, 
significantly decreased RV mass/(LV + septal mass) and 
increased the (LV + septal mass)/heart mass compared to 
MCT alone (p < 0.05).
Echocardiography measurements
In Fig.  1, MCT increased the RV thickness, the RV/LV 
diameter ratio and decreased the TAPSE (p < 0.05 versus 
control). Chronic and moderate consumption of RARW 
significantly limited RV hypertrophy and dysfunction 
(p < 0.05 versus MCT). In Table  2, MCT induced PAH 
as demonstrated by a decrease in PAAT, PAAT/ejection 
time, peak velocity and VIT (p < 0.05 versus control). 
Chronic and moderate treatment of RARW partially 
reversed MCT-induced PAH (p < 0.05 versus MCT).
Plasma lipid peroxidation markers (CD and TBARS) 
and antioxidant activities (SOD and catalase)
The concentration of CD increased in MCT vs controls 
(p < 0.01). Chronic and moderate treatment with RARW 
reversed the MCT-induced PAH -associated CD con-
centration (p < 0.01) as shown in Additional file  2: Fig-
ure S2. The concentration of TBARS increased in MCT 
vs controls (p < 0.01) and in MCT + RARW vs controls 
(p < 0.01). There was a tendency of reduction in the 
MCT + RARW group compared with the MCT groups 
but it was not significant. There were no significant 
changes in SOD and catalase activities after consumption 
of RARW, see Additional file 2: Figure S2.
Determination of cardiac fibrosis
No changes of cardiac fibrosis occurred following the 
injection of MCT (p > 0.05). Chronic and moderate treat-




























































Fig. 1 The effect of chronic, moderate and reduced‑alcohol red wine on biometric and cardiac parameters. Rats were divided into 4 groups: those 
who consumed water (Control), reduced‑alcohol wine (RARW) and/or those who received an injection of PAH‑inducing MCT. All rats consumed 
the respective beverages for 7 days before until 28 days after the MCT injection. a Effect of moderate, chronic treatment of RARW on the right 
ventricular free wall in MCT‑induced PAH. b Effect of moderate, chronic treatment of RARW on the ratio of the RV diameter to LV diameter in MCT 
induced PAH. c Effect of moderate, chronic treatment of RARW on the Tricuspid Annular Plane Systolic excursion in MCT induced PAH. C Control, 
MCT Monocrotaline, RARW Reduced‑alcohol red wine, RV Right ventricle. Values are mean ± S.E.M. *p < 0.05 (vs C); †p < 0.05 (vs MCT); n ≥ 5 per 
group
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control or MCT treated rats (p > 0.05), as shown in Addi-
tional file 3: Figure S3.
Discussion
In the present study, we used an established in  vivo rat 
model of PAH to study the potential cardiovascular ben-
efit of chronic and moderate consumption of RARW on 
cardiac dysfunction associated with PAH. Our data show, 
for the first time to our knowledge, that chronic and 
moderate consumption of RARW confers cardiovascu-
lar protection in an MCT-induced PAH model. Indeed, 
28 days after MCT injection, PAH was characterised by 
an increase in RV hypertrophy and an alteration of the 
pulmonary artery flow. The daily treatment with moder-
ate RARW in this PAH rat model reduced RV hypertro-
phy and improved pulmonary artery flow. Interestingly, 
this beneficial effect was associated with reduced lipid 
peroxidation.
Epidemiological studies consistently support the view 
that alcoholic beverages confer cardiovascular ben-
efits in a J-shape curve fashion with maximal protec-
tion obtained for 1–2 glasses per day for women and 
2–3 glasses per day for men [18]. There is no doubt that 
excessive consumption of alcohol produces detrimental 
effects on the cardiovascular system and other systems 
[19]. It is therefore critical to keep the alcohol content 
to a minimal intake so that cardiovascular benefit can be 
observed without any well-known side effects of the alco-
hol. To this end, we had previously established an animal 
rat model mimicking the human setting of chronic and 
moderate consumption of wine (equivalent to 1–2 glasses 
per day) to demonstrate that chronic and moderate con-
sumption of RARW (6% alcohol by volume) could confer 
the same cardioprotective benefits against ischemia–rep-
erfusion injuries as a regular wine (12% alcohol by 
volume) [4]. In the present study, we used the same pro-
tocol to demonstrate the cardiovascular benefit of RARW 
(thus limiting any potential side effects of the alcohol) in 
an in vivo animal model of pulmonary hypertension.
The potential benefit of chronic and moderate alco-
holic beverage against pulmonary hypertension has 
been poorly studied in both clinical and experimental 
settings. Although a lower risk of chronic obstructive 
pulmonary disease is observed with moderate alcohol 
consumption in humans [6], no clear scientific evidence 
on the amount and duration of alcoholic beverage con-
sumption is available [20]. Using both morphometric and 
Table 2 Echocardiography measurements 28 days after MCT injection
Rats consumed wine for 7 days before and 28 days after being injected with PAH‑inducing MCT
Values are mean ± S.E.M
C Control, MCT Monocrotaline, RARW Reduced‑alcohol red wine, bpm Heart rate, IVS inter‑ventricular septum, LVID left ventricle internal diameter (mm) , LVPW left 
ventricle posterior wall, (mm), Peak E maximum velocity of mitral E wave (m/s), Peak A maximum velocity of mitral A wave (m/s), PAAT pulmonary artery acceleration 
time (m/s), VTI velocity time integral (mm)
*p < 0.05 (vs C); †p < 0.05 (vs MCT); n ≥ 5 per group
C MCT RARW MCT + RARW 
Heart rate (bpm) 414 ± 26 362 ± 22 415 ± 39 397 ± 18
Left ventricle
 IVS, diastole (mm) 1.75 ± 0.08 1.56 ± 0.23 1.61 ± 0.06 1.59 ± 0.09
 IVS, systole (mm) 3.08 ± 0.14 2.85 ± 0.30 2.82 ± 0.07 2.75 ± 0.27
 LVID, diastole (mm) 8.28 ± 0.32 7.90 ± 0.32 8.19 ± 0.29 8.12 ± 0.34
 LVID, systole (mm) 4.98 ± 0.41 4.86 ± 0.46 5.02 ± 0.27 4.80 ± 0.37
 LVPW, diastole (mm) 1.79 ± 0.16 1.79 ± 0.16 1.81 ± 0.12 1.73 ± 0.09
 LVPW, systole (mm) 2.76 ± 0.28 2.78 ± 0.20 2.84 ± 0.21 2.66 ± 0.15
 Shortening fraction (%) 40 ± 3 35 ± 8 37 ± 2 44 ± 3
 Ejection fraction (%) 67 ± 4 68 ± 5 67 ± 2 72 ± 3
Mitral flow
 Peak E (m/s) 1143 ± 178 979 ± 89 1127 ± 97 1080 ± 57
 Peak A (m/s) 1040 ± 193 871 ± 53 855 ± 79 987 ± 71
 E/A ratio 1.1 ± 0.1 1.1 ± 0.2 1.3 ± 0.1 1.1 ± 0.1
Pulmonary artery flow
 PAAT (m/s) 23.43 ± 1.64 13.95 ± 0.95* 22.14 ± 1.40 18.93 ± 1.80*,†
 PAAT/Ejection time 0.32 ± 0.02 0.18 ± 0.02* 0.34 ± 0.02† 0.25 ± 0.03
 Peak velocity (m/s) 1235 ± 71 978 ± 62* 1218 ±  54† 1111 ± 32
 VTI (mm) 56 ± 2 36 ± 5* 53 ±  2† 46 ± 2
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echocardiographic measurements, our data provide solid 
evidence for a reduction of right ventricular hypertro-
phy associated with chronic and moderate consumption 
of RARW in a rat model of PAH. The use of echocardi-
ography is a useful technique to measure pulmonary 
acceleration time as an alternative index to assess right 
ventricular systolic pressure in a non-invasive manner 
in PAH rats [21]. Currently, treatment in patients suf-
fering from PAH has limited effect on mortality and the 
quality of life, does not cure the disease and only limits 
the progression of the disease [2]. Here, we show that 
chronic and moderate consumption of RARW could 
effectively reduce cardiovascular damage associated with 
PAH in a well-established preclinical model. Interest-
ingly, epidemiological studies suggest that wine may con-
fer superior health benefits compared to other alcoholic 
beverages, an effect that would be attributed, at least in 
part, to the various cardioprotective components that are 
present in the wine [5]. Unfortunately, very little experi-
mental work has been performed in this field. Alcohol 
alone, given chronically at the concentration equivalent 
to 2–3 glasses of wine, does not confer cardioprotection 
against ischemia–reperfusion injury [4]. Other bioac-
tive compounds such as resveratrol and melatonin, given 
chronically at the concentration found in wine, can pro-
tect against ischemia–reperfusion injury [22]. Grape 
juice, which contains similar phenolic compounds to 
wine, increases endothelial nitric oxide synthase activ-
ity, decreases right ventricular end diastolic pressure and 
lipid peroxidation in MCT-induced cor pulmonale [23]. 
These studies, combined with our present study, strongly 
support the knowledge that the alcohol may not be the 
main component in wine to account for the cardiopro-
tective effect of chronic and moderate consumption of 
RARW. It would therefore be of interest to test whether 
moderate and chronic consumption of grape juice or red 
wine after complete removal of alcohol may still confer 
any cardiovascular benefit in a rat model of PAH.
The mechanisms responsible for the cardiac altera-
tions in PAH still remain to be understood, although the 
presence of an oxidative stress may precipitate the harm-
ful events leading to right ventricular cardiac hypertro-
phy (see review) [2]. Oxidative stress, a consequence of 
oxidants and antioxidants imbalance is associated with 
excess reactive species that may cause damage to biologi-
cal systems, requiring repair and detoxification [24]. High 
consumption of antioxidants such as those found in red 
wine can decrease oxidative stress levels and contribute 
to health protection [25]. In the current study, moderate 
to chronic consumption of RARW significantly reduced 
CD similar to the findings already described in the litera-
ture with wine or dealcoholized wine [26, 27]. Significant 
reduction in oxidants after wine consumption suggests 
that moderate and chronic red wine consumption could 
protect against lipid peroxidation in the circulation [28, 
29].
Conclusion
In conclusion, chronic and moderate consumption of 
RARW decreased MCT-induced PAH, lessened RV 
hypertrophy and dysfunction, an effect which is associ-
ated with a reduction of lipid peroxidation. The results 
of this study suggest that chronic moderate consumption 
of RARW or its components may represent a promising 
new protective strategy to limit cardiovascular dysfunc-
tion in PAH.
Limitations
Using MCT-induced PAH rats to study the effects of 
reduced-alcohol wine over a short period of time on 
potential cardioprotection, as well as on oxidative stress, 
is a relevant model. However, there are possible limita-
tions of the study that need to be taken into considera-
tion. The rats consumed RARW for 7  days prior to the 
MCT-injection. It is possible that this duration of treat-
ment was insufficient to achieve maximal protection 
before the injection of MCT. Some studies have sug-
gested that a cardioprotective effect of regular mod-
erate consumption of alcohol might only be observed 
after 6  weeks of chronic drinking. To better mimic the 
natural conditions of wine drinking, the red wine could 
have been given at specific times during a 24-h period, 
by intragastric gavage. This would more closely mimic 
the human conditions where wine is consumed undi-
luted, often at specific times of the day, but would have 
increased the complexity of the study. Adding a control 
group of rats that consumed alcohol only might have pro-
vided information about the cardioprotective effect of 
the alcohol itself compared with the other components 
in wine. In our study, we used CD and TBARS assays to 
assess oxidative stress. These assays are still widely used 
due to their cost-effectiveness and ease of method. How-
ever, more accurate and sensitive (but often more costly 
and time-consuming) techniques to assess lipid peroxida-
tion and oxidative stress are available.
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Additional file 1: Figure S1. Summarised experimental protocol of the 
study. Rats were divided into 4 groups: those who consumed water (Con‑
trol), reduced‑alcohol wine (RARW) and/or those who received an injec‑
tion of PAH‑inducing MCT. All rats consumed the respective beverages for 
7 days before until 28 days after the MCT injection. MCT: Monocrotaline; 
RARW: Reduced‑alcohol red wine; SOD: Superoxide dismutase; CD: Conju‑
gated dienes; TBARS: Thiobarbituric acid reactive substances.
Additional file 2: Figure S2. The effect of chronic, moderate and 
reduced‑alcohol red wine on oxidative stress parameters and antioxi‑
dants in controls and PAH rats. Rats were divided into 4 groups: those 
who consumed water (Control), reduced‑alcohol wine (RARW) and/or 
those who received an injection of PAH‑inducing MCT. All rats consumed 
the respective beverages for 7 days before until 28 days after the MCT 
injection. a Effect of moderate, chronic treatment of RARW on plasma 
conjugated dienes in MCT induced PAH. b Effect of moderate, chronic 
treatment of RARW on plasma TBARS in MCT induced PAH. c Effect of 
moderate, chronic treatment of RARW on plasma superoxide dismutase 
in MCT14induced PAH. d Effect of moderate, chronic treatment of RARW 
on plasma catalase in MCT induced PAH. C: Control; MCT: Monocrotaline; 
RARW: Reduced‑alcohol red wine; CD: Conjugated dienes. Values are 
mean ± S.E.M. *p< 0.05 (vs C); †p<0.05 (vs MCT); n ≥ 5 per group.
Additional file 3: Figure S3. Determination of cardiac fibrosis in controls 
and PAH rats. Rats were divided into 4 groups: those who consumed water 
(Control), reduced‑alcohol wine (RARW) and/or those who received an 
injection of PAH‑inducing MCT. All rats consumed the respective bever‑
ages for 7 days before until 28 days after the MCT injection. a Effect of 
moderate, chronic treatment of RARW on cardiac fibrosis in MCT induced 
PAH. b Histology section of hearts (RV) stained with 0.1% Sirius red in 
picric acid to access cardiac fibrosis at 20X magnification. Data are from 
control rats and post MCT rats at day 28. C: Control; MCT: Monocrotaline; 
RARW: Reduced‑alcohol red wine; RV: Right ventricle; LV: Left ventricle. 
Values are mean ± S.E.M. p>0.05; n ≥ 5 per group.
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